Paul Thompson

Company: Mission Therapeutics

Job title: CSO

Seminars:

Novel DUB Inhibitor Platform Addressing Protein Homeostasis 9:00 am

Mission has developed a world-leading potent and selective DUB inhibitor library Selective tools provide best method for elucidating DUB enzyme regulation of disease pathophysiology USP30 inhibitors exemplify progression from hit to candidate, with more DUB target programs to followRead more

day: Day Two